Our top pick for
Building a portfolio
Sutro Biopharma, Inc is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 182 staff and has a trailing 12-month revenue of around USD$45.7 million.
|Latest market close||USD$22.04|
|52-week range||USD$6 - USD$19.18|
|50-day moving average||USD$14.7789|
|200-day moving average||USD$10.8841|
|Wall St. target price||USD$21|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.441|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||N/A|
|1 month (2020-12-24)||-0.18%|
|3 months (2020-10-20)||N/A|
|6 months (2020-07-20)||N/A|
|1 year (2020-01-20)||N/A|
|2 years (2019-01-20)||N/A|
|3 years (2018-01-20)||N/A|
|5 years (2016-01-20)||N/A|
Valuing Sutro Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sutro Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sutro Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Sutro Biopharma shares trade at around 38x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Revenue TTM||USD$45.7 million|
|Gross profit TTM||USD$-22,876,000|
|Return on assets TTM||-15.96%|
|Return on equity TTM||7.13%|
|Market capitalisation||USD$648.6 million|
TTM: trailing 12 months
There are currently 2.6 million Sutro Biopharma shares held short by investors – that's known as Sutro Biopharma's "short interest". This figure is 1.7% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Sutro Biopharma shares can be evaluated.
Sutro Biopharma's "short interest ratio" (SIR) is the quantity of Sutro Biopharma shares currently shorted divided by the average quantity of Sutro Biopharma shares traded daily (recently around 236293.27272727). Sutro Biopharma's SIR currently stands at 11. In other words for every 100,000 Sutro Biopharma shares traded daily on the market, roughly 11000 shares are currently held short.
However Sutro Biopharma's short interest can also be evaluated against the total number of Sutro Biopharma shares, or, against the total number of tradable Sutro Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sutro Biopharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Sutro Biopharma shares in existence, roughly 70 shares are currently held short) or 0.0771% of the tradable shares (for every 100,000 tradable Sutro Biopharma shares, roughly 77 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sutro Biopharma.
Find out more about how you can short Sutro Biopharma stock.
We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $6 up to $19.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.4535. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.